Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152804 | 1.00 | PGR (0.39) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL15255661 | 0.88 | PGR (0.39) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL9923372 | 0.87 | AKT1 (0.41) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL14161428 | 0.85 | EGLN2 (0.38) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL361749 | 0.85 | AKT1 (0.40) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL13256652 | 0.84 | PGR (0.37) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL3052055 | 0.84 | EGLN2 (0.38) | PGREGLN2ABCB1GPR119DRD2 | |
| SCHEMBL15401804 | 0.83 | NPC1 (0.43) | DRD2 | |
| SCHEMBL10167174 | 0.83 | NPC1 (0.43) | DRD2 | |
| SCHEMBL15401802 | 0.83 | NPC1 (0.43) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077810-A1 | Inhibitors Of AKT Activity | MERCK SHARP & DOHME LLC | 2012-03-29 | — | — | US | disclosed |
| EP-2413932-A1 | INHIBITORS OF AKT ACTIVITY | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114780-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077810-A1 | Inhibitors Of AKT Activity | PIK3CA, PIK3CD, PIK3CB | PGR 1830/4885EGLN2 3016/4885ABCB1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.